Floatz logo

Trabectedin

Ovarian Epithelial Cancer Recurrent

AGO Research GmbHSmall moleculePhase 4 / ApprovedDormant
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
95/ 100

Competitive context

245 Active assets in the Ovarian Epithelial Cancer Recurrent cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Carboplatin
University of Washington
Phase 3BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Palbociclib
University Medical Center Groningen
Phase 4BB

View all 50 →

Same molecule, other indications

Trabectedin is also rated in:

ovarian neoplasmDormant
B
Indicative ·
63 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
63 / 100
View asset →
ovarian cancerDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →